Skip to main content
Clinical Trials/NCT01056666
NCT01056666
Completed
Phase 4

Evaluation de l'Impact Sur la qualité de Vie de l'Utilisation d'un système Collecteur Conveen( étuis pénien Conveen Optima Avec Poches de Recueil Conveen) Chez Des Hommes Souffrant d'Une Incontinence Urinaire modérée ou sévère, Comparativement à Leur Protection Absorbante Habituelle

Coloplast A/S0 sites61 target enrollmentJune 2007

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Urinary Incontinence
Sponsor
Coloplast A/S
Enrollment
61
Primary Endpoint
Impact on quality of life
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The objective of this investigation is to asses with validated scales, the impact on the quality of life of men suffering of moderate to severe incontinence of the use of Conveen Optima urisheath in comparison with their usual absorbent protection.

Registry
clinicaltrials.gov
Start Date
June 2007
End Date
March 2009
Last Updated
14 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient over 18
  • Out clinic patient
  • Patient using absorbent protection for his urinary incontinence
  • Moderate to severe urinary incontinence (1 hour pad test \> 10g)
  • All kind of stable urinary incontinence
  • Patient able to apply himself the device
  • Patient able to understand the questions
  • Patient having given his informed consent
  • Patient whose overall treatment for his urinary incontinence is not modified during the study

Exclusion Criteria

  • Patient having a retracted penis
  • Patient having skin problem on the penis
  • Patient using urisheaths
  • Bedridden patient
  • Institutionalized patient
  • Patient with indwelling catheter or under intermittent catheterisation
  • Patient with fecal incontinence leading to the use of absorbent protection
  • Patient suffering of urinary tract infection

Outcomes

Primary Outcomes

Impact on quality of life

Time Frame: Days 0, 15, 30

Secondary Outcomes

  • Efficacy (leakages)(days 13, 14, 15 and days 28, 29, 30)

Similar Trials